Bing

SEARCH HISTORY

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. Trade-Ideas LLC identified Array BioPharma ( ARRY) as a weak on high ...
The Street · 1 day ago
Array Biopharma (NASDAQ:ARRY)‘s stock had its “buy” rating reiterated by Piper Jaffray in a research note issued on Wednesday, MarketBeat reports. Shares of Array Biopharma (NASDAQ:ARRY) traded down 1.19% during mid-day trading on …
Ticker Report · 7/22/2015
Zacks upgraded shares of Array Biopharma (NASDAQ:ARRY) from a hold rating to a buy rating in a research report released on Tuesday morning, MarketBeat Ratings reports. The firm currently has $7.50 price target on the biopharmaceutical company’s …
wkrb13.com · 7/24/2015
More from Bing News
... has given a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $9.93. Array Biopharma (NASDAQ:ARRY) traded down 1.34% during mid-day trading on Wednesday …
sleekmoney.com · 7/22/2015
Array Biopharma's stock is down 4.0% to $6.46 on heavy trading volume. Today's volume of 2.6 million shares tops the average 30-day volume of 1.6 million shares. Unusually high volume can signify a potential turning point or validate a breakout.
Financial News Network Online · ByPeter Chu · 7/22/2015
Healthcare stocks rose broadly on Wall Street so far on Monday, with the sector seeing an overall increase of 0.6%. More broadly, the Dow Jones Industrial Average pushed 0.4% higher, the Nasdaq rose 0.7% and the S&P 500 was up 0.4%. Some of the …
Investor Place · 3/2/2015
Array Biopharma Inc (NASDAQ:ARRY) stock rallied 22.7% in extended trading on Wednesday after it announced that it had entered into a new agreement with Novartis AG (ADR) (NYSE:NVS). The deal will allow Array to regain the marketing and …
bidnessetc.com · 12/4/2014
About Selumetinib and Uveal Melanoma Selumetinib is an oral small molecule MEK inhibitor invented by Array BioPharma (NASDAQ: ARRY) and licensed to AstraZeneca in 2003. AstraZeneca is responsible for …
Financial Content · 7/22/2015
Uveal Melanoma
Recently, the 50 Day Moving Average for ARRY broke out above the 200 Day Simple Moving Average, suggesting a short-term bullish trend. This has already started to take place, as the stock has moved higher by 21% in the past four weeks. Plus, the …
NASDAQ · 1/2/2015
Array BioPharma, Inc. (ARRY) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for ARRY broke out above the 200 Day …
Yahoo Finance · 1/2/2015